Specifically, a variety of monoclonal antibodies have been tested on several solid tumors or hematologic malignancies, providing promising results, whereas research has been conducted towards a creation of a protein with the ability to block EPH/ephrin interactions [19]. This evidence concerns the gene EPHA1 and hematologic disorder.